Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (909)	3/26/1999 3:08:00 PM
From: Harold Engstrom	Read Replies (2) \| Respond to of 1686

Should amend previous post to read Amevive market of $3B+ and Antova market of $1.6B (instead of millions) to reflect what the cited article actually said (instead of what my fat fingers actually typed).

To: Harold Engstrom who wrote (909)	3/29/1999 2:34:00 PM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 1686

Biogen Plans to Overtake Schering in MS Treatments, FAZ Says Bloomberg News March 29, 1999, 3:16 a.m. PT Frankfurt, March 29 (Bloomberg) -- Biogen Inc., one of the world's most successful biotechnology companies, expects its multiple sclerosis treatment Avonex will overtake Schering AG's Betaferon this year as the top seller in the $1 billion MS drug market, Biogen Chairman James Vincent said in an interview with the Frankfurter Allgemeine Zeitung. ''In any case, it's our goal to realize sales of more than $550 million this year and with that to overtake the current market leader,'' Vincent said in the interview, pointing out that Biogen had Avonex sales of about $395 million in 1998 while Germany's Schering sold 720 million deutsche marks ($396 million) worth of Betaferon. Promising products in Biogen's development pipeline include Amreve, now in the first clinical-test phase, for the treatment of psoriasis, skin disorder, and Antova, to stop the body's rejection of transplanted organs, Vincent told the newspaper. Biogen's former chief executive Jim Tobin quit last year after disagreements with Vincent and sold his 719,000 shares in the Cambridge, Massachusetts-based company early this year, bringing him about $67 million.